文献速递炎症性肠病

维多珠单抗诱导克罗恩病内镜与组织学缓解

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
PubMed 文献 · Gastroenterology · 2019-06-05

这项前瞻性研究纳入110例活动性克罗恩病患者,开放标签给予维多珠单抗(300 mg,第0、2、6周,此后每8周至52周)。第26和52周分别有33%和36%患者达到内镜缓解(SES-CD<4);第26周组织学缓解率基于Geboes评分为64%、基于Robarts组织病理学指数为66%。第22周血清维多珠单抗浓度>10 mg/L与第26周内镜缓解相关。

要点

  • 约三分之一患者在第26和52周达到内镜缓解(SES-CD<4)。
  • 第26周组织学缓解率基于Geboes评分为64%,基于RHI为66%。
  • 第22周血清维多珠单抗浓度>10 mg/L与第26周内镜缓解相关。

核心结论

  • 约三分之一克罗恩病患者在维多珠单抗治疗52周后达到内镜缓解,约三分之二在第26周达到组织学缓解。
  • 较高的血清维多珠单抗浓度与更好的结局相关。

研究设计与样本

  • 前瞻性研究,纳入110例活动性克罗恩病患者(CDAI>220且存在黏膜溃疡),开放标签给予维多珠单抗300 mg静脉输注。
  • 输注方案为第0、2、6周,此后每8周至第52周;若第10周CDAI未下降70分则追加一次输注。
  • 基线、第26周和第52周行回结肠镜检查并取活检,由本地和中心阅片者判定SES-CD评分;第26周组织学特征由盲法病理学家评估。
  • 研究在欧洲三级中心进行;血清维多珠单抗浓度在系列时间点测量。

主要发现

  • 第26周有36例(29%)、第52周有34例(31%)达到无皮质类固醇临床缓解(CDAI<150)。
  • 意向性分析显示,第26周有36例(33%)、第52周有40例(36%)达到内镜缓解(SES-CD<4)。
  • 内镜应答(SES-CD评分下降≥50%)在第26周有44例(40%)、第52周有5例(45%)发生。
  • 在基线有炎症的配对活检分析中,第26周组织学缓解基于Geboes评分为43/67例(64%),基于Robarts组织病理学指数为37/56例(66%)。
  • 较低SES-CD评分患者的血清维多珠单抗浓度在第2、10和22周更高;第22周血清浓度>10 mg/L与第26周内镜缓解相关。

关键数值与推荐

  • 内镜缓解定义为SES-CD评分<4。
  • 内镜应答定义为SES-CD评分下降≥50%。
  • 临床缓解定义为CDAI评分<150且无皮质类固醇。
  • 组织学缓解分别基于Geboes评分和Robarts组织病理学指数评估。
  • 第22周血清维多珠单抗浓度>10 mg/L与第26周内镜缓解相关。

临床怎么用

  • 维多珠单抗可用于诱导克罗恩病患者的内镜和组织学缓解。
  • 监测血清维多珠单抗浓度可能有助于预测内镜缓解。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the ability of vedolizumab to induce endoscopic and histologic remission in patients with Crohn's disease (CD). METHODS: We performed a prospective study of 110 patients with active CD, based on CD activity index (CDAI) scores >220 and mucosal ulcerations, who received open-label vedolizumab (300 mg) infusions at weeks 0, 2, and 6, and every 8 weeks thereafter through week 52 at tertiary centers in Europe. Patients received an additional infusion at week 10 if their CDAI score had not decreased by 70 points. Patients underwent ileocolonoscopy with collection of biopsies at baseline and weeks 26 and 52; a local and central reader determined simple endoscopic index for CD (SES-CD) scores. Histologic features were assessed by a blinded pathologist at week 26. Serum concentrations of vedolizumab were measured at serial time points. The primary outcome was endoscopic and histologic remission in patients with active CD treated with vedolizumab for 52 weeks. RESULTS: At weeks 26 and 52, 36 patients (29%) and 34 patients (31%), respectively, were in corticosteroid-free clinical remission (CDAI score <150), respectively. Based on intent-to-treat analysis, endoscopic remission (SES-CD score <4) was achieved by 36 patients (33%) and 40 patients (36%) at weeks 26 and 52. Endoscopic responses (decrease in SES-CD score ≥50%) occurred in 44 patients (40%) at week 26 and 5 patients (45%) at week 52. Serum concentrations of vedolizumab were higher at weeks 2, 10, and 22 in patients with lower SES-CD scores. Histologic remission at week 26 was observed in 43 (64%) of 67 patients based on Geboes Score and 37 (66%) of 56 patients based on Robarts Histopathology Index scores in analyses of paired biopsies with inflammation at baseline. Serum concentrations of vedolizumab above 10 mg/L at week 22 were associated with endoscopic remission at week 26. CONCLUSIONS: In a prospective trial, we found that approximately one-third of patients with CD achieve endoscopic remission after 52 weeks of treatment with vedolizumab and two-thirds achieve histologic remission at week 26. Higher serum concentrations of vedolizumab were associated with better outcomes. EUDRACT no: 2014-005376-29.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology. 2019. PMID: 31175865. doi:10.1053/j.gastro.2019.05.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。